Julius Strauss, ESMO 2021: Long-term Follow-up of Patients with HPV–associated Malignancies Treated with Bintrafusp Alfa
touchONCOLOGY joins Dr Julius Strauss (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA), to discuss the long-term follow-up of patients with human papillomavirus–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
1. What are the unmet needs in the treatment of human papillomavirus (HPV)-associated cancers? (00:15-01:37)
2. What is bintrafusp alfa and what is the rationale for its use in this treatment setting? (01:37-02:49)
3. Could you tell us a little about the INTR@PID 001 study and its findings? (02:49-04:38)
4. What have we learned from the latest longer-term data from this study? (04:38-05:00)
5. What will be the next step in the clinical development of bintrafusp alfa in HPV-associated malignancies? (05:00-06:29)
Disclosures: Julius Strauss is listed as a co-inventor on an NIH patent evaluating dual blockade of TGFβ and PDL1 for HPV associated malignancies.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In Gynaecological Cancers
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results – Chemotherapy with tegafur-uracil for locally advanced cervical cancer
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]
Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer
Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!